Paradigm Biopharmaceuticals Ltd PBIGF
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.00–0.01
- 52-Week Range
- $0.00–0.35
- Bid/Ask
- $0.00 / $0.01
- Shares Outstanding
- 626.43M
- Market Cap
- $2.50M
- Volume/Avg
- 65,750 / 60,133
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 58.40
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. Its activities are conducted across Australia, the United States, Hong Kong, and Moldova through global clinical development programs and strategic research collaborations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
Valuation
|
Metric
|
PBIGF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.10 |
Price/Sales | 58.40 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PBIGF
|
|---|---|
Quick Ratio | 1.07 |
Current Ratio | 1.10 |
Interest Coverage | −22.06 |
Quick Ratio
PBIGF
Profitability
|
Metric
|
PBIGF
|
|---|---|
Return on Assets (Normalized) | −209.21% |
Return on Equity (Normalized) | −534.27% |
Return on Invested Capital (Normalized) | −331.55% |
Return on Assets
PBIGF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^DGf>% | LOCK|^kg$ | $129B | |||
| Moderna Inc
MRNA
| LOCK|?FbW$h$ | LOCK|zK% | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|hM%ZS?> | LOCK|m?!B< | $79B | |||
| argenx SE ADR
ARGX
| LOCK|^rh$S> | LOCK|Xx | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Q%^<D## | LOCK|<<@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gj<J$s | LOCK|g>!td | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@F%sxMB^ | LOCK|>fdr | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|$SSppP< | LOCK|S?w | $24B | |||
| Incyte Corp
INCY
| LOCK|%@rW@?r | LOCK|dK | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&HSjQ&M | LOCK|CX | $14B |
United States